Pfizer gets FDA accelerated approval for Braftovi

Pfizer (NYSE:PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies as a first-line treatment for metastatic colorectal cancer, or mCRC, with a BRAF gene mutation.

The agency approved the medication, also known as encorafenib, to be